Clinical Trial

Selumetinib for NF2-Related Schwannomatosis

Name: Selumetinib for NF2-Related Schwannomatosis — clinical trial record (NCT07707947)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASSIST

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors.

Trial Details

NCT Number	NCT07707947
Lead Sponsor	Beijing Tiantan Hospital Collaborators: AstraZeneca
Conditions	Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma, Ependymoma, Vestibular Schwannoma
Enrollment	20 participants
Start Date	2026-07-15
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-16